A Phase II Study of MLN8237 Alone and in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas
Phase of Trial: Phase II
Latest Information Update: 08 Jun 2018
Price : $35 *
At a glance
- Drugs Alisertib (Primary) ; Rituximab (Primary)
- Indications B-cell lymphoma; Burkitt's lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
- Focus Therapeutic Use
- 03 May 2018 Status changed from active, no longer recruiting to discontinued.
- 15 Jul 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Dec 2016.
- 16 Oct 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.